lopinavir/ritonavir / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 77 Diseases   69 Trials   69 Trials   4434 News 


«12345678910111213...4546»
  • ||||||||||  Actemra IV (tocilizumab) / Roche, JW Pharma
    Low Dose Radiotherapy in the Management of COVID-19 Pneumonia (LOWRAD-Cov19): Final Results (Henry B. Gonzalez Convention Center, Exhibit Hall 1) -  Aug 1, 2022 - Abstract #ASTRO2022ASTRO_959;    
    LD-RT is a feasible and well-tolerated treatment that may lead to rapid clinical improvement. Large randomized trials should be done to establish the efficacy of LD-RT to treat COVID-19 pneumonia.
  • ||||||||||  hydroxychloroquine / Generic mfg., azithromycin / Generic mfg., lopinavir/ritonavir / Generic mfg.
    Journal:  Safety of Drugs Used during the First Wave of COVID-19: A Hospital-Registry-Based Study. (Pubmed Central) -  Jul 29, 2022   
    Although most ADRs recovered without sequelae, fatal cases were described, even though the role of the disease could not be completely ruled out. In similar situations, efforts should be made to use the drugs in the context of clinical trials, and to limit off-label use to those drugs with a better benefit/risk profile in specific situations and for patients at high risk of poor disease prognosis.
  • ||||||||||  hydroxychloroquine / Generic mfg., mycophenolate mofetil / Generic mfg., lopinavir/ritonavir / Generic mfg.
    Review, Journal:  Covid-19 in kidney transplant recipients with immunosuppressive therapy. (Pubmed Central) -  Jul 27, 2022   
    In addition, reviewing of 47 papers with 851 samples showed that immunosuppressant medications alone could be a therapeutic choice in kidney transplants infected with COVID-19 with careful management. Patients with organ transplantation infected with COVID-19 may show different clinical signs, clinical course, and prognosis due to underlying diseases and the use of immunosuppressant medications. It might be best to continue taking the immunosuppressant medications but modify them based on the patients' conditions such as clinical symptoms, laboratory results, paraclinical examinations.
  • ||||||||||  Observational data, Retrospective data, Journal, Adverse drug reaction:  The evaluation of adverse drug reactions in Saudi Arabia: A retrospective observational study. (Pubmed Central) -  Jul 13, 2022   
    Two deaths resulted from salbutamol and cefazolin use...In our study, most drugs used as antimicrobial, cardiovascular, and hematologic therapies were associated with a higher risk of developing severe and serious events. We recommend monitoring and using medications optimally to ensure patient safety.
  • ||||||||||  Evusheld (cilgavimab/tixagevimab) / AstraZeneca, Rebif (human IFN-?-1a) / EMD Serono
    Enrollment closed, Trial completion date, Trial primary completion date:  DisCoVeRy: Trial of Treatments for COVID-19 in Hospitalized Adults (clinicaltrials.gov) -  Jul 5, 2022   
    P3,  N=2416, Active, not recruiting, 
    We recommend monitoring and using medications optimally to ensure patient safety. Recruiting --> Active, not recruiting | Trial completion date: Mar 2023 --> Oct 2023 | Trial primary completion date: Mar 2023 --> Jul 2022
  • ||||||||||  ethambutol / Generic mfg.
    PK/PD data, Retrospective data, Journal:  Population pharmacokinetics of ethambutol in African children: a pooled analysis. (Pubmed Central) -  Jul 2, 2022   
    To obtain exposure within the 2-6 mg/L recommended range for Cmax, the current doses must be doubled (or tripled with HIV+ children on lopinavir/ritonavir) for paediatric patients. This raises concerns regarding the potential for ocular toxicity, which would require evaluation.
  • ||||||||||  lopinavir/ritonavir / Generic mfg.
    Journal:  AI-Aided Design of Novel Targeted Covalent Inhibitors against SARS-CoV-2. (Pubmed Central) -  Jul 2, 2022   
    The drug repurposing of known approved drugs (e.g., lopinavir/ritonavir) has failed to treat SARS-CoV-2-infected patients...All of the 47 lead compounds obtained directly with our AI model and related derivatives based on the SBOP are accessible in our molecular library. These compounds can be used as potential candidates by researchers to develop drugs against SARS-CoV-2.
  • ||||||||||  ribavirin / Generic mfg., lopinavir/ritonavir / Generic mfg.
    Retrospective data, Journal:  Characteristics of liver function changes in 111 elderly patients with COVID-19 pneumonia (Pubmed Central) -  Jun 30, 2022   
    Elderly COVID-19 patients have a higher proportion of abnormal liver function, and patients in the severe group are more likely to have higher level of TB, AST, ALP and GGT. The abnormal liver function may be related to the direct viral infection of the liver and the inflammatory immune response of the body after infection in elderly patients.
  • ||||||||||  hydroxychloroquine / Generic mfg., azithromycin / Generic mfg., lopinavir/ritonavir / Generic mfg.
    Retrospective data, Journal:  Treatments for SARS-CoV2 infection: a retrospective study of drug-drug interactions and safety (Pubmed Central) -  Jun 29, 2022   
    The abnormal liver function may be related to the direct viral infection of the liver and the inflammatory immune response of the body after infection in elderly patients. Despite risk of adverse drug reactions and DDIs related to drugs used in SARS-CoV-2 infection, few iatrogenics diseases were found.
  • ||||||||||  azithromycin / Generic mfg., lopinavir/ritonavir / Generic mfg.
    Journal:  ADRS due to COVID-19 in midterm pregnancy: successful management with plasma transfusion and corticosteroids. (Pubmed Central) -  Jun 28, 2022   
    Despite risk of adverse drug reactions and DDIs related to drugs used in SARS-CoV-2 infection, few iatrogenics diseases were found. Judicious corticosteroid therapy along with convalescent plasma transfusion to suppress viremia and cytokine storm can lead to favorable outcome in the pregnant women with ARDS caused by SARS-CoV infection without superimposed bacterial infection.
  • ||||||||||  lopinavir/ritonavir / Generic mfg.
    Trial completion date:  TREATNOW: Trial of Early Therapies During Non-hospitalized Outpatient Window for COVID-19 (clinicaltrials.gov) -  Jun 28, 2022   
    P2,  N=600, Active, not recruiting, 
    Judicious corticosteroid therapy along with convalescent plasma transfusion to suppress viremia and cytokine storm can lead to favorable outcome in the pregnant women with ARDS caused by SARS-CoV infection without superimposed bacterial infection. Trial completion date: Jun 2022 --> Sep 2022
  • ||||||||||  Viracept (nelfinavir) / ViiV Healthcare, Roche
    Journal:  Aspartyl Protease Inhibitors as Anti-Filarial Drugs. (Pubmed Central) -  Jun 25, 2022   
    In vitro testing against the adult gastro-intestinal nematode Trichuris muris suggested broad-spectrum potential for these APIs. This study suggests that APIs may serve as new leads to be further explored for drug discovery to treat parasitic nematode infections.
  • ||||||||||  ivermectin oral / Generic mfg.
    Biomarker, Review, Journal:  Will the Use of Pharmacogenetics Improve Treatment Efficiency in COVID-19? (Pubmed Central) -  Jun 25, 2022   
    There are many types of available COVID-19 therapies, including antiviral agents (remdesivir, lopinavir/ritonavir, oseltamivir), antibiotics (azithromycin), antiparasitics (chloroquine, hydroxychloroquine, ivermectin), and corticosteroids (dexamethasone)...The knowledge of pharmacogenetic issues, which translate into variability in drug conversion from prodrug into drug, metabolism as well as transport, could help to predict treatment efficiency and the occurrence of adverse effects in patients. However, many drugs used for the treatment of COVID-19 have not undergone pharmacogenetic studies, perhaps as a result of the lack of time.
  • ||||||||||  ivermectin oral / Generic mfg.
    Journal:  Impact of COVID-19 therapy on hyperglycemia. (Pubmed Central) -  Jun 14, 2022   
    Individualized /personalized patient care is required for diabetic mellitus patients with COVID-19 infection. Improper drug therapy aggravates hyperglycemic conditions and other comorbid conditions, leading to increased morbidity and mortality.
  • ||||||||||  Journal:  Transcriptional Effects of Candidate COVID-19 Treatments on Cardiac Myocytes. (Pubmed Central) -  Jun 11, 2022   
    The results of the differential gene expression analysis are available for interactive access at https://covid19drugs.jakobilab.org. Transcriptional profiling in hiPSC-CMs treated with COVID-19 drugs identified unfavorable changes with lopinavir/ritonavir and lopinavir/ritonavir/INF-β in key cardiac gene programs that may negatively affect heart function.
  • ||||||||||  atazanavir / Generic mfg.
    Review, Journal:  Effectiveness and Safety of Atazanavir Use for the Treatment of Children and Adolescents Living With HIV: A Systematic Review. (Pubmed Central) -  Jun 10, 2022   
    Atazanavir/ritonavir is recommended as a preferred second-line antiretroviral regimen in children older than 3 months, alternatively to lopinavir/ritonavir...The comparative cohort compared atazanavir to darunavir, with few grade 3-4 adverse events, except transient hyperbilirubinemia, occurring in half (92/188) of the atazanavir patients...The use of atazanavir/ritonavir in children and adolescents needs further investigation, but remains a suitable option for a preferred second-line antiretroviral regimen. CRD42022309230.
  • ||||||||||  Journal:  Effects of Drugs Formerly Suggested for COVID-19 Repurposing on Pannexin1 Channels. (Pubmed Central) -  Jun 5, 2022   
    Favipiravir, hydroxychloroquine, lopinavir, and the combination of lopinavir with ritonavir were found to inhibit pannexin1 channel activity without affecting pannexin1 protein or mRNA levels. Thusthree new inhibitors of pannexin1 channels were identified that, though currently not being used anymore for the treatment of COVID-19 patients, could be potential drug candidates for other pannexin1-related diseases.
  • ||||||||||  ivermectin oral / Generic mfg.
    Review, Journal:  Adverse Audio-Vestibular Effects of Drugs and Vaccines Used in the Treatment and Prevention of COVID-19: A Review. (Pubmed Central) -  Jun 4, 2022   
    (3) In accordance with EBM (evidence-based medicine) the treatment of COVID-19 by using lopinavir/ritonavir, chloroquine and hydroxychloroquine, azithromycin, favipiravir, amantadine, oseltamivir, and ivermectin is no longer recommended for patients suffering from COVID-19 due to a lack of clinical data, publications, and recommendations...However, there is still a need to monitor ototoxic side-effects because of potential interactions with other ototoxic drugs. Many of the drugs approved by EMA and FDA are new, and not every side-effect is known.
  • ||||||||||  atorvastatin / Generic mfg.
    Clinical, Journal:  Survival of the hospitalized patients with COVID-19 receiving Atorvastatin: a randomized clinical trial. (Pubmed Central) -  May 22, 2022   
    The median hospitalization days in the intervention group was longer (P < 0.001) and remission in the comparison group occurred 1.71 times sooner (Hazard ratios (HR) = 1.70, CI95%=1.22-2.38, P=0.002). Totally, adding atorvastatin to the standard regime in this study increased hospitalization days and imposed negative effects on symptom improvement in hospitalized patients with COVID-19.
  • ||||||||||  Eurartesim (dihydroartemisinin/piperaquine) / Medicines for Malaria Venture, Leadiant Biosci
    Trial completion, Trial completion date:  DPART: Dihydroartemisinin-Piperaquine in the Context of Antiretroviral Therapy (clinicaltrials.gov) -  May 20, 2022   
    P4,  N=190, Completed, 
    No abstract available Recruiting --> Completed | Trial completion date: Dec 2022 --> Apr 2022
  • ||||||||||  Isentress (raltegravir) / Merck (MSD)
    RALTEGRAVIR: AN OPTION FOR CHILDREN WITH DYSLIPIDEMIA RELATED TO ANTIRETROVIRAL THERAPY. () -  May 19, 2022 - Abstract #ESPID2022ESPID_946;    
    She was born by vaginal delivery at 37 weeks and a four-week zidovudine prophylaxis regimen was performed...Abacavir, lamivudina and lopinavir/ritonavir were initiated...Learning Points/ In children treated with PIs, metabolic complications could compromise the benefits of adequate viral suppresion. Integrase inhibitors (eg. raltegravir) appear to be a valid alternative due to a neutral effect on lipid profile.
  • ||||||||||  hydroxychloroquine / Generic mfg., ceftriaxone / Generic mfg., lopinavir/ritonavir / Generic mfg.
    Clinical, Journal:  Focal superior quadrant haemorrhages in post COVID-19 patient: A target for personalized medicine. (Pubmed Central) -  May 19, 2022   
    In this report, we focused on the origin of retinal bleeding in a post COVID-19 patient, likely due to a focal occlusion of a vessel. Considering the nature of SARS-CoV-2 infection, we hypothesize that retinal haemorrhages were caused by a combination of factors including the patient's antiplatelet therapy and the thrombotic microvascular injury caused by the virus.
  • ||||||||||  ivermectin oral / Generic mfg.
    Journal:  Immune-related therapeutics: an update on antiviral drugs and vaccines to tackle the COVID-19 pandemic. (Pubmed Central) -  May 12, 2022   
    This article also presents the intellectual groundwork for the ongoing development of vaccines in preclinical and clinical trials, explaining potential candidates (live attenuated-whole virus vaccines, inactivated vaccines, subunit vaccines, DNAbased vaccines, protein-based vaccines, nanoparticle-based vaccines, virus-like particles and mRNA-based vaccines). Designing and developing an effective vaccine (both prophylactic and therapeutic) would be a long-term solution and the most effective way to eliminate the COVID-19 pandemic.